^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PF-08046052

i
Other names: PF-08046052, SGN-EGFRd2, LAVA-1223, LAVA-224×223, LAVA1223, LAVA224×223, PF08046052, LAVA 1223, LAVA 224×223, PF 08046052
Associations
Company:
LAVA Therap, Pfizer
Drug class:
EGFR inhibitor, γδ TCR modulator
Related drugs:
Associations
1year
A Study of SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=275, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
EGFR mutation • MSI-H/dMMR • ALK rearrangement • EGFR rearrangement
|
PF-08046052
over1year
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
EGFR mutation • MSI-H/dMMR • ALK rearrangement • EGFR rearrangement
|
PF-08046052